• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Renier J Brentjens, Marco L Davila, +22 authors Michel Sadelain
  • Medicine
  • Science translational medicine
  • 2013 (First Published: 20 March 2013)
  • Adults with relapsed B cell acute lymphoblastic leukemia (B-ALL) have a dismal prognosis. Only those patients able to achieve a second remission with no minimal residual disease (MRD) have a hope forContinue Reading
  • Renier J Brentjens, Isabelle Riviére, +24 authors Michel Sadelain
  • Medicine
  • Blood
  • 2011 (First Published: 3 November 2011)
  • We report the findings from the first 10 patients with chemotherapy-refractory chronic lymphocytic leukemia (CLL) or relapsed B-cell acute lymphoblastic leukemia (ALL) we have enrolled for treatmentContinue Reading
  • Bianca D Santomasso, Jae Hoo Park, +18 authors Renier J Brentjens
  • Biology, Medicine
  • Cancer discovery
  • 2018 (First Published: 1 August 2018)
  • CD19-specific chimeric antigen receptor (CAR) T-cell therapy is highly effective against relapsed or refractory acute lymphoblastic leukemia (ALL), but is hindered by neurotoxicity. In 53 adultContinue Reading
  • Jae Hyun Park, Isabelle Riviére, +10 authors Renier J Brentjens
  • Medicine
  • 2014 (First Published: 6 December 2014)
  • Background: Relapsed adult acute lymphoblastic leukemia (ALL) is associated with high reinduction mortality, chemotherapy resistance, and dismal prognosis with a median overall survival (OS) < 6Continue Reading
  • Sham Mailankody, Arnab Ghosh, +34 authors Eric Smith
  • Medicine
  • 2018 (First Published: 29 November 2018)
  • Introduction: BCMA targeted CAR T cell therapy has shown promising results in patients with relapsed/refractory multiple myeloma (MM). Herein, we report on the safety and efficacy of MCARH171, aContinue Reading
  • Jae Hong Park, Isabelle Riviére, +8 authors Renier J Brentjens
  • Medicine
  • 2015 (First Published: 3 December 2015)
  • Background: We have previously reported high anti-tumor activity of autologous T cells genetically modified to express 19-28z chimeric antigen receptor (CAR) targeting CD19 in adult patients withContinue Reading
  • Jae Hong Park, Maria Lia Palomba, +11 authors Michel Sadelain
  • Medicine
  • 2018 (First Published: 29 November 2018)
  • Background: CD19-specific 2nd generation chimeric antigen receptor (CAR) T cell therapy with either CD28 or 41BB co-stimulatory domain has demonstrated complete remission (CR) rates of 30-50% inContinue Reading